Good judgement by District Court of The Hague explaining inventive step

Recently District Court of The Hague has given a judgement in a case between Sandoz and Glaxo regarding a combination patent owned by Glaxo.

Sandoz requested revocation of Glaxo’s combination patent and supplementary protection certificate (“SPC”) for a composition containing the beta-agonist salmeterol and the corticosteroid fluticasone proprionate for simultaneous inhalation in the treatment of respiratory diseases mainly asthma.
Read full article here

Advance notice to innovator for launch at risk is compulsory???

Recently, the U.S. District Court for the Southern District of New York ruled that a generic player may not be required to submit or provide advance notice to the innovator of their intent to launch at-risk a competing product in Teva et al. v. Sandoz, Inc., 08-7611 (S.D.N.Y. October 12, 2010).
This decision is noteworthy in that it contrasts with the practice in the District Court of New Jersey where at least one generic company has been ordered to provide advance notice to the brand companies of an impending at-risk launch.
For full details click here